{
    "id": "correct_subsidiary_00047_1",
    "rank": 5,
    "data": {
        "url": "https://www.bioworld.com/articles/382243-stiefel-plans-640m-acquisition-of-dermatology-firm-connetics",
        "read_more_link": "",
        "language": "en",
        "title": "Stiefel Plans $640M Acquisition Of Dermatology Firm Connetics",
        "top_image": "https://www.bioworld.com/icons/favicon-32x32.png",
        "meta_img": "https://www.bioworld.com/icons/favicon-32x32.png",
        "images": [
            "https://www.bioworld.com/images/Cortellis_Flagship_Logo.png",
            "https://www.bioworld.com/images/Cortellis_Flagship_Logo_TM_RGB_Color.png",
            "https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration1.png?height=355&t=1613684293&width=640",
            "https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Stock-merger-illustration.png?height=355&t=1620238968&width=640",
            "https://www.bioworld.com/ext/resources/Ads/2024/bioworld-advertising-reach.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "Biologics",
            "Biopharmaceutical",
            "Biotechnology",
            "Drug",
            "EMA",
            "FDA",
            "Health",
            "Medical",
            "Medical device",
            "Medical technology",
            "Pharmaceutical"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Privately held Stiefel Laboratories Inc.'s acquisition of Connetics Corp. for $640 million represents a happy ending - or beginning - for the firm previously known as Connective Therapeutics Inc. (BioWorld Today)",
        "meta_lang": "en",
        "meta_favicon": "/icons/apple-touch-icon.png",
        "meta_site_name": "",
        "canonical_link": "https://www.bioworld.com/articles/382243-stiefel-plans-640m-acquisition-of-dermatology-firm-connetics",
        "text": "Today's news in brief\n\nBioWorld briefs for July 19, 2024.\n\nToday's news in brief\n\nBioWorld MedTech briefs for July 19, 2024.\n\nDaiichi Sankyo reports orexin OX2 receptor agonists for narcolepsy\n\nDaiichi Sankyo Co. Ltd. has prepared and tested new 2-azabicyclo[3.1.1]heptane compounds acting as orexin OX2 receptor agonists with potential for the treatment...\n\nOrum scores potential $945M deal with Vertex for novel DACs\n\nOrum Therapeutics Inc. struck a potential $945 million (â‚©1.3 trillion) deal with Vertex Pharmaceuticals Inc. to discover novel degrader antibody conjugates (DAC)..."
    }
}